Jaime Mejia
Advertisement
Articles by Jaime Mejia
46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study
ByHeather McArthur, MD, MPH,Peter A. Fasching,Rebecca Dent, MD,Javier Cortés, MD,Lajos Pusztai, MD, DPhil,Sherko Kuemmel,Carsten Denkert,Yeon Hee Park,Rina Hui,Nadia Harbeck, MD, PhD,Masato Takahashi,Seock-Ah Im,Michael Untch, MD, PhD,Marie-Ange Mouret-Reynier,Theodoros Foukakis,Marta Ferreira,Fatima Cardoso,Yu Ding,Cecilia Pinheiro,Jaime Mejia,Joyce A. O’Shaughnessy,Peter Schmid, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Ficerafusp Alfa/Pembrolizumab Receives FDA BTD in Front-Line HNSCC
2
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
3
64Cu-SAR-bisPSMA PET Detects More Prostate Cancer Lesions vs SOC
4
FDA Grants Fast Track Designation to NG-350A For pMMR Rectal Cancer
5
